FDA Final Guidance on Post-Approval Safety Data Reporting

FDA Guidance Documents

Published March 2nd, 2026

Detected March 4th, 2026

Summary

The FDA has issued final guidance on post-approval safety data reporting, updating standards for managing and reporting individual case safety reports. This guidance clarifies the use of new data sources and replaces previous versions from 2003 and a draft from March 2024.

View original document View source feed page

What changed

The FDA has released final guidance titled "E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports." This guidance, developed under the International Council for Harmonisation (ICH), updates previous recommendations by clarifying the use of emerging data sources such as social media, market research programs, and patient support programs for post-approval safety monitoring. It supersedes the 2003 guidance and a draft issued in March 2024, updating terminology and standards for expedited adverse event reporting.

This final guidance provides updated definitions and standards for the management and reporting of individual case safety reports (ICSRs) for pharmaceutical products. While the guidance is non-binding, it represents the FDA's current thinking and is crucial for ensuring compliance with post-market safety surveillance requirements. Companies should review the updated guidance to ensure their safety data management and reporting processes align with the clarified standards, particularly concerning the integration of new data sources. The FDA accepts comments on guidance documents at any time.

What to do next

Review the final guidance on post-approval safety data reporting.
Update internal processes for managing and reporting individual case safety reports to incorporate new data sources and terminology.
Ensure alignment with ICH E2D(R1) standards for pharmacovigilance.

Source document (simplified)

Search for FDA
Guidance Documents

Docket Number: FDA-2024-D-0803 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research Center for Biologics Evaluation and Research

ICH Website

E2D(R1) Explanatory Note

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports.” The guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance updates the 2003 guidance titled “E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting,” by clarifying the use of new or increasingly used data sources (e.g., social media, market research programs, patient support programs). This final guidance clarifies the use of new postapproval safety sources and update terminology and standards for postapproval adverse event reporting. The guidance replaces the draft guidance “E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports” issued on March 14, 2024, and the final guidance issued September 15, 2003.